HIND

Vyome Holdings Inc

Jun 05 • 02:01PM ET

2.28

-0.02 -1.09 %

Healthcare • Biotechnology • USA • Nano • NASD

Peers: CMMB COCP CVKD HCWB INAB LEXX MTVA NCEL OSRH XCUR

Index	-	P/E	-	EPS (ttm)	-12.41	Insider Own	52.82%	Shs Outstand	7.02M	Perf Week	-2.78%
Market Cap	15.96M	Forward P/E	-	EPS next Y	-0.92	Insider Trans	0.00%	Shs Float	3.31M	Perf Month	3.41%
Enterprise Value	8.48M	PEG	-	EPS next Q	-0.19	Inst Own	1.48%	Short Float	3.72%	Perf Quarter	-18.75%
Income	-13.25M	P/S	11.91	EPS this Y	85.33%	Inst Trans	-0.74%	Short Ratio	3.86	Perf Half Y	-54.59%
Sales	1.34M	P/B	2.37	EPS next Y	-29.79%	ROA	-159.01%	Short Interest	0.12M	Perf YTD	-33.87%
Book/sh	0.96	P/C	1.81	EPS next 5Y	43.86%	ROE	-332.39%	52W High	20.76 -89.04%	Perf Year	-86.62%
Cash/sh	1.25	P/FCF	-	EPS past 3/5Y	98.04% 93.71%	ROIC	-196.50%	52W Low	1.75 30.00%	Perf 3Y	-99.98%
Dividend Est.	-	EV/EBITDA	-	Sales past 3/5Y	-69.47% -50.98%	Gross Margin	48.16%	Volatility	8.13% 7.81%	Perf 5Y	-100.00%
Dividend TTM	-	EV/Sales	6.33	EPS Y/Y TTM	98.53%	Oper. Margin	-401.91%	ATR (14)	0.16	Perf 10Y	-
Dividend Ex-Date	-	Quick Ratio	4.27	Sales Y/Y TTM	-81.26%	Profit Margin	-985.46%	RSI (14)	55.55	Recom	1.00
Dividend Gr. 3/5Y	- -	Current Ratio	4.27	EPS Q/Q	-100.19%	SMA20	6.05%	Beta	1.50	Target Price	11.50
Payout	-	Debt/Eq	0.00	Sales Q/Q	-97.16%	SMA50	5.37%	Rel Volume	0.39	Prev Close	2.30
Employees	18	LT Debt/Eq	0.00	Earnings	May 28 BMO	SMA200	-43.91%	Avg Volume	31.92K	Price	2.28
IPO	Oct 06, 2016	Option/Short	No / Yes	EPS/Sales Surpr.	0.00% -	Trades		Volume	8,765	Change	-1.09%

May-28-26 08:00AM	Vyome Holdings Reports First Quarter 2026 Results With Key FDA Filings and Strong Balance Sheet (Business Wire)
May-12-26 08:00AM	Vyome Strikes Deal With Impetis Biosciences, Opening A ~$57B Market Opportunity (Business Wire)
Apr-22-26 08:00AM	Vyome Presents Transformational VT-1953 Phase 2 Clinical Study Data at Prestigious AACR 2026 (Business Wire)
Apr-06-26 08:00AM	Vyome to Present Compelling Phase 2 Clinical Data on VT-1953 for Treatment of MFW at AACR 2026 (Business Wire)
Mar-30-26 07:00PM	Vyome Holdings Inc (HIND) Q4 2025 Earnings Call Highlights: Strategic Advances Amid Financial ... (GuruFocus.com) +5.39%
08:00AM	Loading…
Mar-26-26 08:00AM	Vyome Reports Transformational 2025 Results: Company Well Positioned for Breakout Phase (Business Wire)
Feb-24-26 08:00AM	Livechain Completes Acquisition of Senior, Secured Debt of Humanyze, An MIT Incubated, AI Enabled HR Analytics Company (Business Wire) +8.28%
Feb-18-26 09:00AM	Vyome Announces the Publication of Positive Preclinical Results in Uveitis, Addressing a $3B Potential Market Opportunity (Business Wire) +6.84%
Feb-11-26 07:00AM	Vyome Files for VT-1953 Orphan Drug Status, Furthers Strategic Focus On VT-1953 Program Over the Next 6 Months (Business Wire)
Feb-02-26 07:00AM	Vyome Successfully Capitalizes All VT-1953 Funding Requirements For Initial Phase 3 Results (Business Wire) +14.58%
Jan-27-26 08:00AM	Independent Analyst Values Vyomes VT-1953 at USD 1 Billion Upon Successful Completion of Phase 3 Study (Business Wire)
Dec-22-25 08:00AM	Vyome Subsidiary LiveChain (LICH) to Acquire Senior Secured Note in Humanyze, An MIT Incubated Company (Business Wire) +5.43%
Dec-08-25 08:00AM	Vyome Reports Positive Final Phase 2 Results for VT-1953; Plans to Advance Into Pivotal Study For FDA Approval (Business Wire) +14.37%
Nov-25-25 07:00AM	Vyome Appoints Renowned Medical Oncologist, Dr. Aditya Bardia, as Senior Medical Advisor to Guide the Development of MFW Program (Business Wire)
Nov-18-25 07:00AM	Vyome Holdings Announces Transformational First Quarter Following Nasdaq Listing (Business Wire)
09:04AM	Loading…
Nov-04-25 09:04AM	Vyome Holdings Announces Results of Annual Shareholder Meeting (Business Wire)
Sep-29-25 07:00AM	Vyome Holdings Acquires MIT AI Spinout Oculo Health (Business Wire)
Sep-17-25 07:00AM	Vyome Presents Strong Data Showing Topical VT-1908 is an Effective Treatment for Uveitis, Opening Up a $3B Addressable Market Opportunity (Business Wire)
Sep-09-25 08:30AM	Vyome Holdings Strengthens Leadership Team with Industry Veterans as it plans Pivotal Trial Studies (Business Wire)
Sep-04-25 08:30AM	Vyome Holdings Announces Positive Interim Data from Phase 2 Study of VT-1953 in Malignant Fungating Wounds (MFW) and Provides Update on MFW market opportunity (Business Wire) -9.06%
Aug-21-25 07:00AM	Vyome Signs MoU with Embryyo, India's Leading Medical Device Innovation Studio (Business Wire) +21.91%
Aug-18-25 08:30AM	Vyome Announces Strategic Review of Livechain (OTCID: LICH) (Business Wire) -37.64%
Aug-15-25 02:57PM	Vyome to leverage US-India ties to tackle $100B immuno-inflammatory market (Investing.com) -10.71%
08:00AM	Vyome To Mark First Day of Trading as HIND with Nasdaq Opening Bell (Business Wire)
Aug-14-25 07:18PM	Vyome closes Merger Transaction, Will Trade on Nasdaq as HIND Tomorrow (Business Wire) +22.50%

Vyome Holdings, Inc. engages in the development of immuno-inflammatory assets. It focuses on therapeutic solutions that target formulations for site-targeted applications. The company was founded on January 2, 2008 and is headquartered in Cambridge, MA.

Co-FounderMr. Venkateswarlu Nelabhotla M.B.A.

Ph.D.Dr. Shiladitya Sengupta M.Sc.

Chief Financial OfficerMr. Robert Dickey IV

Chief Technology OfficerDr. Richard Fahrner Ph.D.

Senior Vice President of Product Development & Regulatory CMCDr. Charles G. Chavdarian Ph.D.

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

HIND

Vyome Holdings Inc

Upgrade your Finviz experience